Binding affinity studies of 1,2,3-triazole copper(II) complexes to human serum albumin

Abstract

Two copper(II) complexes with tetradentate 1,4-disubstituted-1,2,3-triazole ligands, [CuL(MeCN)](ClO₄)₂ (1) and [CuL′](ClO₄)₂ (2), have been prepared and characterized by different techniques, including X-ray structure determination, spectroscopic, and electrochemical measurements, as reported elsewhere. Herein, we report the interactions of these complexes, and corresponding free ligands, with human serum albumin (HSA) verifying their relative thermodynamic stability and differences in binding to this protein. Interactions with HSA were verified by CD measurements monitored at 564?nm, up to stoichiometric ratio 2:1 [Complex]:[protein], according to competitive equilibria involving the insertion of copper at the selective N-terminal metal binding site in HSA, and additionally at a secondary nonselective site. Further interactions of these complexes with L-tryptophan residues, and probable supplementary site(s) for the binding, were followed by fluorescence measurements. Analogous experiments with the free L and L′ indicated much weaker interactions. Protein oxidation damage was observed for both complexes, monitored by carbonyl groups formation in the presence of H₂O₂, probably with the participation of reactive oxygen species. Density functional theory calculations exhibit metal-ligand binding interaction energies similar to [Cu(HSA-N_terminal)]⁺, and reinforced the experimental results, showing clearly that such triazole ligands are competitive toward copper(II) in biological medium.     

Insight into the binding evaluation of two antitumor Pd(II) complexes with human serum albumin

The interaction between two novel water-soluble palladium(II) complexes (Pd(bpy)(pyr-dtc)]NO₃, complex I and ([Pd(phen)(pyr-dtc)]NO₃, complex II, where bpy = 2,2′-bipyridine, phen = 1,10-phenanthroline and pyr-dtc = pyrrolidinedithiocarbame) and human serum albumin (HSA) was investigated by fluorescence quenching spectroscopy, synchronous, fluorescence resonance energy transfer (FRET) and three-dimensional fluorescence combined with UV–Vis absorption spectroscopy and circular dichroism technique under simulative physiological conditions. Fluorescence analysis demonstrated that the quenching mechanism of HSA by Pd(II) complexes was static fluorescence quenching and hydrogen bonds and van der Waals interactions were the main intermolecular force based on thermodynamic data. The HSA–Pd(II) complex interaction had a high affinity of 10⁵ M^?1, and the number of binding sites n is almost 1. The results of synchronous fluorescence, three-dimensional fluorescence spectra, UV–Vis absorption and CD spectroscopy indicated that these two complexes may induce the microenvironment around the tryptophan residues and the conformation of human serum albumin. The binding distance (r) in the interaction between Pd(II) complex and HSA was estimated by the efficiency of fluorescence resonance energy transfer (FRET). Furthermore, results from multiple spectroscopic studies are consistent and indicate that the antitumor Pd(II) complexes can efficiently bind with human serum albumin molecules, providing a reasonable model that can help in understanding the design, transportation and toxic effects of anticancer agents.     

Platinum metallodrug-protein binding studies by capillary electrophoresis-inductively coupled plasma-mass spectrometry: characterization of interactions between Pt(II) complexes and human serum albumin

Characterizing how platinum metallocomplexes bind to human serum albumin (HSA) is essential in evaluating anticancer drug candidates. Using cisplatin as a reference complex, the application of capillary electrophoresis (CE) to reliably assess drug/HSA interactions was validated. Since this complex is small compared to the size of the protein, the binding response could only be recognized when applying CE coupled to a (platinum) metal-specific mode of detection, namely inductively coupled plasma-mass spectrometry (ICP-MS). This coupling allowed for confirmation of a specific affinity of cisplatin and novel Pt complexes to HSA, measurement of the kinetics of binding reactions, and determination of the number of drug molecules attached to the protein. As the cisplatin/HSA molar ratio increased, the reaction rate became faster with a maximum on the kinetic curve appearing at about 50 h of incubation at 20 times excess of cisplatin. The reaction was characterized as a pseudo-first order reaction with the rate constant k = 0.003 min(-1) at 37 degrees C. When incubated with a 20-fold excess of cisplatin, HSA bound up to 10 mol of Pt per mol of the protein. This is indicative for a strong metal-protein coordination occurring at several HSA sites other than the only protein cysteine residue. Structural analogs of cisplatin, bearing aminoalcohol ligands, showed comparable protein binding reactivity and stoichiometry but a common equilibrium was not reached even after one week of incubation. Also apparent was a two-step mechanism of the binding reaction. Results demonstrated the suitability of CE-ICP-MS as a rapid assay for high-throughput studying of drug/HSA interactions.     

Cu(II), Fe(III)与人血清白蛋白相互作用的荧光光谱研究

通过研究Cu(II),Fe(III)对人血清白蛋白(HSA)内源荧光的猝灭,探讨了Cu(II),Fe(III)与人血清白蛋白的结合机理。基于Forster非辐射能量转移机理。获得了人血清白蛋白第一类Cu(II)结合部位与214位色氨酸残基间的距离为1.8nm,并讨论了Cu(II),Fe(III)与HSA结合的差异。     

人血清白蛋白与Cu(II)配合物的生物活性研究

Cu(II)配合物很有可能成为下一代的抗肿瘤药物。本文以2-氨基-5-氯苯酚和2-喹啉甲醛合成的席夫碱作为配体,与Cu(II)络合形成配合物1。分别对配合物1和其与人血清白蛋白(HSA)的复合物HSA-1进行体外抗肿瘤测试,发现HSA能提高配合物1的抗肿瘤活性,并降低了对正常细胞的毒性。通过线粒体膜电位等实验,可以推断出配合物1是通过线粒体通路诱导癌细胞凋亡。     

Exploring binding properties of gliclazide with human serum albumin

Journal of Thermal Analysis and Calorimetry - The thermodynamic parameters of the binding of gliclazide (GL) with human serum albumin (HSA) have been discussed along with the insight into the...     

Synthesis of lanthanide(III) complexes appended with a diphenylphosphinamide and their interaction with human serum albumin

Two DOTA-based proligands bearing a pendant diphenylphosphinamide 4a and 4b were synthesised. Their Eu(III) complexes exhibit sensitised emission when excited at 270 nm via the diphenylphosphinamide chromophore. Hydration states of q = 1.5 were determined from excited state lifetime measurements (Eu.4a $ k_{{{\text{H}}_{ 2} {\text{O}}}} = 2. 1 4 \,{\text{ms}}^{ - 1} ,\;k_{{{\text{D}}_{ 2} {\text{O}}}} = 0. 6 4 \,{\text{ms}}^{ - 1} $ ; Eu.4b $ k_{{{\text{H}}_{ 2} {\text{O}}}} = 2. 6 7\, {\text{ms}}^{ - 1} ,\;k_{{{\text{D}}_{ 2} {\text{O}}}} = 1. 1 8 \,{\text{ms}}^{ - 1} $ ). In the presence of human serum albumin (HSA) (0.1 mM Eu.4a/b, 0.67 mM HSA, pH 7.4) q = 0.4 for Eu.4a ( $ k_{{{\text{H}}_{ 2} {\text{O}}}} = 1. 3 4\, {\text{ms}}^{ - 1} ,\;k_{{{\text{D}}_{ 2} {\text{O}}}} = 0. 7 5\, {\text{ms}}^{ - 1} $ ) and q = 0.6 for Eu.4b ( $ k_{{{\text{H}}_{ 2} {\text{O}}}} = 1. 8 3\, {\text{ms}}^{ - 1} ,\;k_{{{\text{D}}_{ 2} {\text{O}}}} = 1.0 5 \,{\text{ms}}^{ - 1} $ ). Relaxivites (pH 7.4, 298 K, 20 MHz) of the Gd(III) complexes in the absence and presence of HSA (0.1 mM Gd.4a/b, 0.67 mM HSA) were: Gd.4a (r ₁ = 7.6 mM^?1s^?1 and r ₁ = 11.7 mM^?1s^?1) and Gd.4b. (r ₁ = 7.3 mM^?1s^?1 and r ₁ = 16.0 mM^?1s^?1). These relatively modest increases in r ₁ are consistent with the change in inner-sphere hydration on binding to HSA shown by luminescence measurements on Eu.4a/b. Binding constants for HSA determined by the quenching of luminescence (Eu) and enhancement of relaxivity (Gd) were Eu.4a (27,000 M^?1 ± 12%), Eu.4b (32,000 M^?1 ± 14%), Gd.4a (21,000 M^?1 ± 15%) and Gd.4b (26,000 M^?1 ± 15%).     

铈配合物与人血清白蛋白相互作用的研究

在生理条件(pH=7.4)下,利用荧光光谱和紫外光谱探讨了华法灵铈与人血清白蛋白(HSA)的相互作用。根据荧光和紫外光谱可知,华法灵铈配合物对人血清白蛋白荧光产生猝灭作用,其猝灭方式为静态猝灭。并通过Stern-Volmer方程等,计算出了配合物与人血清白蛋白的静态猝灭常数、结合常数和结合位点数。根据一系列热力学参数ΔH,ΔS,ΔG的相对大小,确定出配合物与人血清白蛋白的主要作用力类型为静电作用力。且用同步荧光法讨论了华法灵铈对HSA构象的影响。     

Ruthenium(II) complexes of pyrrol-azo ligands: cytotoxicity,interaction with calf thymus DNA and bovine serum albumin

Two ruthenium(II) complexes of newly designed pyrrol-azo ligands(L) and bipyridine(bpy) formulated as [Ru(L)(bpy)₂]ClO₄, where HL^1?=?(4-chloro-phenyl)-(1H-pyrrol-2-yl)-diazene (1) complex 1 and HL^2?=?(4-nitro-phenyl)-(1H-pyrrol-2-yl)-diazene for 2, were isolated in pure form. The complexes were characterized by physicochemical and spectroscopic methods. The electrochemical behavior of the complexes showed the Ru(III)/Ru(II) couple at different potentials with quasi-reversible voltammograms. The study of cytotoxicity effects of 1 and 2 on human breast cancer cells (MCF 7, MDA-MB 231) and cervical cancer cell (HeLa) taking Cisplatin as a positive reference showed that 1 exhibited higher cytotoxicity against cancer cell lines than 2, but less activity than Cisplatin. The interaction of 1 with calf thymus DNA (CT-DNA) using absorption, emission spectral studies, viscosity-measurement, and electrochemical techniques has been used to determine the binding constant K _b and the linear Stern–Volmer quenching constant K _SV. The results indicate that 1 strongly interacts with CT-DNA in groove binding mode. The interaction of bovine serum albumin (BSA) with 1 was also investigated with the help of spectroscopic tools. Absorption spectroscopy proved the formation of a BSA-[Ru(L¹)(bpy)₂]ClO₄ complex.     

Antifungal activity,DNA and lysozyme binding affinity of Pd(II) and Pt(II) complexes bearing N,N-pyridylbenzimidazole ligand

Abstract

The lysozyme- and DNA-binding affinities of the biologically active cisplatin analogues, Pd(II) (1) and Pt(II) (2) complexes of functionalized N,N-pyridylbenzimidazole ligand, are reported. The electronic transitions were studied by time-dependent density functional theory. Complex 1 exhibits interesting antifungal activity against Candida albicans (MIC?=?32?μg?mL^?1; 64?nM) and Cryptococcus neoformans (MIC?=?16?μg?mL^?1, 32?nM). Complex 1 is covalently bound to DNA and lysozyme via the elimination of the chloride ligand(s). When complex 2 interacts with lysozyme, two adduct peaks are observed in the mass spectrum corresponding to binding of Pt(II) ion to lysozyme.     

NMR relaxometric study of new Gd(III) macrocyclic complexes and their interaction with human serum albumin

Five novel Gd(iii) complexes based on the structure of the heptadentate macrocyclic 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A) ligand have been synthesized and their (1)H and (17)O NMR relaxometric properties investigated in detail. The complexes have been functionalised on the secondary nitrogen atom of the macrocyclic ring with different pendant groups for promoting their ability to interact non-covalently with human serum albumin (HSA). The analysis of the proton relaxivity, measured as a function of pH and magnetic field strength, have revealed that the three complexes bearing a poly(ethylene glycol)(PEG) chain possess a single coordinated water molecule, whereas the complexes functionalised with 1-[3-(2-hydroxyphenyl)]-propyl and 1-[3-(2-carboxyphenyloxy)]-propyl pendant groups have two inner sphere water molecules. The water exchange rates, measured by variable temperature (17)O NMR, cover a broad range of values (from 18 to 770 ns) as a function of their charge, the chemical nature of the substituent and its ability to organize a second sphere of hydration near the water(s) binding site. All the complexes have shown some degree of interaction with HSA, with a stronger binding affinity measured for those bearing an aromatic moiety on the pendant group. However, upon binding the expected relaxation enhancement has not been observed and this has been explained with the displacement of the coordinated water molecules by the protein and formation of ternary adducts.     

Competitive binding affinity of two lanthanum(III) macrocycle complexes toward DNA and bovine serum albumin in water

In the present study, two water-soluble lanthanum(III) hexaaza Schiff base complexes were synthesized and characterized and also theoretically investigated. The interactions of these complexes with DNA and bovine serum albumin (BSA) were studied using different spectroscopic assessments and docking simulation analysis. The DNA docking studies suggested that these two complexes are able to interact with DNA through the minor groove, and also the binding affinity is in the order of La(L¹) > La(L²). Furthermore, the spectral titration was carried out and viscosity measurements were taken. In this regard, protein-binding studies revealed that these complexes quench the intrinsic fluorescence of BSA, and indicated that the possible binding site is located on the vicinity of Trp 213, which is further validated by docking simulation analysis. The in vitro anticancer activities of these complexes indicated that the La(L¹) complex is more effective than the other one and also exhibits a better interaction with DNA.     

氟罗沙星与人血清白蛋白相互作用研究

以光谱技术和微量热技术相结合的方法研究水溶液中氟罗沙星分子及铁存在时与人血清白蛋白之间结合作用的机制,用荧光淬灭法测得两反应的结合常数分别为K=1.19×l05L·mol-1和1.0565×105L·mol-1,结合位点数0.97和0.835.依据Fōrster非辐射能量转移机制,得到氟罗沙星与人血清白蛋白间的结合距离(r=3.23nm).用同步荧光技术考察氟罗沙星对人血清白蛋白构象的影响.微量热法测得氟罗沙星与人血清白蛋白反应的ΔH≈0,ΔS＞0,氟罗沙星分子在铁离子存在时与人血清白蛋白反应的ΔH＜0,并且ΔS＞0表明它们的作用都主要为静电力.由于焓熵互补的作用,两反应的自由能没有发生大的变化.     

Betulinic acid binding to human serum albumin: a study of protein conformation and binding affinity

Betulinic acid (BA) has anti cancer and anti-HIV activity and has been proved to be therapeutically effective against cancerous and HIV-infected cells. Human serum albumin (HSA) is the predominant protein in the blood. Most drugs that bind to HSA will be transported to other parts of the body. Using micro TOF-Q mass spectrometry, we have shown, for the first time that BA isolated from a plant (Tephrosia calophylla) binds to HSA. The binding constant of BA to HSA was calculated from fluorescence data and found to be K(BA)=1.685+/-0.01 x 10(6) M(-1), indicating a strong binding affinity. The secondary structure of the HSA-BA complex was determined by circular dichroism. The results indicate that the HSA in this complex is partially unfolded. Further, binding of BA at nanomolar concentrations of BA to free HSA was detected using micro TOF-Q mass spectrometry. The study revealed a mass increase from 65199 Da (free HSA) to 65643 Da (HSA+drug), where the additional mass of 444 Da was due to bound BA. Based on the results of this study, it is suggested that micro TOF-Q mass spectrometry is useful technique for drug binding studies.     

Study on the interaction of tamiflu and oseltamivir carboxylate with human serum albumin

Oseltamivir phosphate (OP; tamiflu) is an antiviral pro-drug, which is hydrolyzed hepatically to the active metabolite oseltamivir carboxylate (OC). It is the first orally neuraminidase inhibitor that was used in the treatment and prophylaxis of influenza virus A and B infection. Human serum albumin (HSA) is the most abundant of the proteins in the blood plasma and is major transporter for delivering several drugs in vivo. This study was designed to examine the interaction of HSA with oseltamivir phosphate (OP) and oseltamivir carboxylate (OC) in aqueous solution at physiological conditions, using a constant protein concentration and various drug contents. FTIR, UV-Vis spectroscopic methods were used to determine the drugs binding mode, the binding constant and the effects of drug complexation on protein secondary structure. Structural analysis showed that OP and OC bind HSA via polypeptide polar groups with overall binding constants of K(OP-HSA)=3.86(± 1.05)× 10(3)M(-1) and K(OC-HSA)=1.5(±0.45) × 10(2)M(-1). The alterations of protein secondary structure are attributed to a partial destabilization of HSA on drug complexation. The protein secondary structure showed no major alterations at low drugs concentrations (50 μM), whereas at higher content (1mM), decrease of α-helix from 58% (free HSA) to 38% (OP-HSA)-48% (OC-HSA), decrease of random coil from 15% (free HSA) to 2% (OP-HSA)-3% (OC-HSA), increase of β-sheet from 6% (free HSA) to 20% (OC-HSA)-29% (OP-HSA) and turn from 8% (free HSA) to 17% (OC-HSA)-19% (OP-HSA) occurred in the drug-HSA complexes. These observations indicated that low drug content induced protein stabilization, whereas at high drug concentration, a partial protein destabilization occurred in these drug-HSA complexes.     

Synthesis and physicochemical characterization of two gadolinium(III) TTDA-like complexes and their interaction with human serum albumin

Two novel derivatives of TTDA (3,6,10-tri(carboxymethyl)-3,6,10-triazadodecanedioic acid), TTDA-BOM and TTDA-N'-BOM, each having a benzyloxymethyl group, were synthesized. (17)O NMR longitudinal and transverse relaxation rates and chemical shifts of aqueous solutions of their Gd(III) complexes were measured at variable temperature with a magnetic field strength of 9.4 T. The water exchange rate (k(ex)(298)) values for [Gd(TTDA-BOM)(H(2)O)](2-) (117 x 10(6) s(-1)) and [Gd(TTDA-N'-BOM)(H(2)O)](2-) (131 x 10(6) s(-1)) are significantly higher than those of [Gd(DTPA)(H(2)O)](2-) (4.1 x 10(6) s(-1)) and [Gd(BOPTA)(H(2)O)](2-) (3.45 x 10(6) s(-1)). The rotational correlation time (tau) values for [Gd(TTDA-BOM)(H(2)O)](2-) (119 ps) and [Gd(TTDA-N'-BOM)(H(2)O)](2-) (125 ps) are higher than those of [Gd(DTPA)(H(2)O)](2-) (103 ps) and [Gd(TTDA)(H(2)O)](2-) (104 ps). The stepwise stoichiometric binding constants of [Gd(TTDA-BOM)(H(2)O)](2)(-) and [Gd(TTDA-N'-BOM)(H(2)O)](2)(-) bound to HSA are obtained by ultrafiltration studies. Fluorescent probe displacement studies exhibit that [Gd(TTDA-BOM)(H(2)O)](2-) and [Gd(TTDA-N'-BOM)(H(2)O)](2-) can displace dansylsarcosine from HSA with inhibition constants (K(i)) of 1900 and 1600 microM, respectively; however, they are not able to displace warfarin. These results indicate that [Gd(TTDA-BOM)(H(2)O)](2-) and [Gd(TTDA-N'-BOM)(H(2)O)](2-) have a weak binding to site II on HSA. In addition, the mean bound relaxivity (r(1b)) and bound relaxivity (r(1)(b)) values for the [Gd(TTDA-BOM)(H(2)O)](2-)/HSA and [Gd(TTDA-N'-BOM)(H(2)O)](2-)/HSA adducts are obtained by ultrafiltration and relaxivity studies, respectively. The bound relaxivity of these adducts values are significantly higher than those of [Gd(BOPTA)(H(2)O)](2-)/HSA and [Gd(DTPA-BOM(3))(H(2)O)](2-)/HSA. These results also suggest that bound relaxivity is site dependent. In binding sites studies of Gd(III) chelates to HSA, a significant decrease of the relaxation rates (R(1obs)) was observed for the [Eu(TTDA-BOM)(H(2)O)](2-) complex which was added to the [Gd(TTDA-N'-BOM)(H(2)O)](2-)/HSA solution, and this indicated that these Gd(III) complexes share the same HSA binding site. Finally, as measured by the Zn(II) transmetalation process, the kinetic stability of these Gd(III) complexes are significantly higher than that of [Gd(DTPA-BMA)(H(2)O)].     

Pnictogen-thiacrown complexes with Pt(II) and Pd(II)

Platinum(II) and palladium(II) complexes of the trithiacrown [9]aneS(3) containing a range of Group 15 donors are reviewed. These complexes have the general formula [M([9]aneS(3))(L(2))](n+) where L represents at least one Group 15 donor. Complexes involving pnictogens, with the exception of bismuth, are observed. The complexes generally have an elongated square pyramidal geometry with a long distance interaction to the third sulphur of the [9]aneS(3) which forms the apex of the square pyramid. This axial metal-sulphur distance is quite sensitive to the donor properties of L. Poorer donors such as Sb and As ligands show short axial distances whereas the better N donor ligands show longer distances. Pt(II) complexes of the formula [Pt([9]aneS(3))(EPh(3))(2)](2+) (E = P, As, Sb) show a considerable distortion towards a trigonal bipyramidal geometry due to intramolecular π-π interactions. Over seventy of these types of complexes have been crystallographically characterized and are discussed in this article. Other unique features of the complexes, including NMR spectroscopy, redox chemistry, and electronic spectroscopy, are also discussed.     

C-H Activation and C-C coupling of arenes by cationic Pt(II) complexes

The synthesis and characterization of cationic platinum complexes of the type [(R(2)PC(2)H(4)PR(2))PtMe(OEt(2))]BAr(F) (R = Cy, Et) are reported. These electrophilic platinum cations are found to react quantitatively with arenes (benzene, toluene) at room temperature by undergoing intermolecular C-H activation with concomitant C-C coupling to generate complexes of the type [[Pt(R(2)PC(2)H(4)PR(2))](2)(mu-eta(3):eta(3)-biaryl)][BAr(F)](2). The dianionic biaryl ligands in these compounds exhibit a rare mu-eta(3):eta(3)-bis-allyl bonding mode and can be removed from the complex with stoichiometric oxidants to generate the free biaryl and [(R(2)PC(2)H(4)PR(2))Pt(mu-X)](2)[BAr(F)](2) (R = Cy, Et; X = Cl, I). The cationic platinum complexes [(R(2)PC(2)H(4)PR(2))PtMe(OEt(2))]BAr(F) (R = Cy, Et) are also quite reactive with water, forming the bridging hydroxide complexes [(R(2)PC(2)H(4)PR(2))Pt(mu-OH)](2)[BAr(F)](2) (R = Cy, Et). A possible mechanism is proposed for the C-C coupling reaction based upon the structures of these bridging biphenyl complexes, which provides a new perspective for the related palladium-catalyzed oxidative coupling of arenes to form biaryls.     

Zinc(II) complexes of ubiquitin: speciation, affinity and binding features

Intraneuronal inclusions consisting of hypermetallated, (poly-)ubiquitinated proteins are a hallmark of neurodegeneration. To highlight the possible role played by metal ions in the dysfunction of the ubiquitin-proteasome system, here we report on zinc(II)/ubiquitin binding in terms of affinity constants, speciation, preferential binding sites and effects on protein stability and self-assembly. Potentiometric titrations allowed us to establish that at neutral pH only two species, ZnUb and Zn(2)Ub, are present in solution, in line with ESI-MS data. A change in the diffusion coefficient of ubiquitin was observed by NMR DOSY experiments after addition of Zn(II) ions, and thus indicates metal-promoted formation of protein assemblies. Analysis of (1)H, (15)N, (13)Cα and (13)CO chemical-shift perturbation after equimolar addition of Zn(II) ions to ubiquitin outlined two different metal-binding modes. The first involves a dynamic equilibrium in which zinc(II) is shared between a region including Met1, Gln2, Ile3, Phe4, Thr12, Leu15, Glu16, Val17, Glu18, Ile61 and Gln62 residues, which represent a site already described for copper binding, and a domain comprising Ile23, Glu24, Lys27, Ala28, Gln49, Glu51, Asp52, Arg54 and Thr55 residues. A second looser binding mode is centred on His68. Differential scanning calorimetry evidenced that addition of increasing amounts of Zn(II) ions does not affect protein thermal stability; rather it influences the shape of thermograms because of the increased propensity of ubiquitin to self-associate. The results presented here indicate that Zn(II) ions may interact with specific regions of ubiquitin and promote protein-protein contacts.     

Multiple and irreversible binding of cis-diamminedichloroplatinum(II) to human serum albumin and its effect on warfarin binding.

Irreversible bindings of cis-diamminedichloroplatinum(II) (cis-DDP) to human serum albumin (HSA) were investigated in a pH 7.4 buffer containing 0.1 M NaCl at various molar ratios (cis-DDP/HSA) up to 60 over a 14 d period (37 degrees C). The metal binding seemed to reach a plateau when incubated at less than 10 times excess of cis-DDP. As the molar ratio increased, the reaction rate was relatively fast within the first day, followed by a moderate increase in the metal binding. When incubated at 60 times excess of cis-DDP, the metal bound as much as 20 mol per mol of HSA in 14 d. Fluorescence quenching of the metal-bound protein suggested that the tryptophan residue was gradually exposed to a hydrophilic environment as the metal binding increased. Furthermore, cis-DDP cleaved disulfide bonds at the ratio of 1 mol of disulfide bond per 5.3 mol of the metal binding. It was therefore suggested that the metal binding also occurred at several sites other than the disulfide bond. Warfarin binding to the metal-bound protein, examined by fluorescence changes, also decreased with increasing metal binding or cleavage of the disulfide bonds. Thus, cis-DDP bound to multiple sites in addition to the lone sulfhydryl group (Cys-34), suggesting that massive conformational changes of the protein took place.